Literature DB >> 7043781

Localization of sites for 125I-labelled botulinum neurotoxin at murine neuromuscular junction and its binding to rat brain synaptosomes.

J O Dolly, R S Williams, J D Black, C K Tse, P Hambleton, J Melling.   

Abstract

Botulinum neurotoxin, purified to homogeneity from Clostridium botulinum (Type A), was found to be highly neurotoxic (greater than 8 X 10(7) mouse LD50/mg protein). Labelling of this pure neurotoxin with 125I-iodine to high specific radioactivity was achieved without appreciable loss of biological activity. This was used to demonstrate saturable binding sites for this toxin at the neuromuscular junction, following in vivo administration into mice. A demonstrable inhibitory effect of the neurotoxin on release of acetylcholine from rat cerebrocortical synaptosomes indicates that it affects synapses in the central nervous system. Kinetic studies on the binding of 125I-labelled neurotoxin to brain synaptosomes yielded an association rate constant of 2.3 x 10(5)M-1s-1; dissociation plots were biphasic and the predominant species showed a rate constant of 1.2 X 10(-4)s-1. The saturable binding component is heat-sensitive and inactivated by trypsin. Preliminary studies showed that botulinum neurotoxin associates with plasma membrane fractions of synaptosomes and that binding does not result in any gross structural changes, at least in the majority of the toxin molecules.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7043781     DOI: 10.1016/0041-0101(82)90183-0

Source DB:  PubMed          Journal:  Toxicon        ISSN: 0041-0101            Impact factor:   3.033


  8 in total

Review 1.  Clostridium botulinum toxins: a general review of involvement in disease, structure, mode of action and preparation for clinical use.

Authors:  P Hambleton
Journal:  J Neurol       Date:  1992-01       Impact factor: 4.849

Review 2.  Temporal characteristics of botulinum neurotoxin therapy.

Authors:  Frank J Lebeda; Regina Z Cer; Robert M Stephens; Uma Mudunuri
Journal:  Expert Rev Neurother       Date:  2010-01       Impact factor: 4.618

3.  Gangliosides interact with synaptotagmin to form the high-affinity receptor complex for botulinum neurotoxin B.

Authors:  Alessandra Flores; Jorge Ramirez-Franco; Richard Desplantes; Kévin Debreux; Géraldine Ferracci; Florian Wernert; Marie-Pierre Blanchard; Yves Maulet; Fahamoe Youssouf; Marion Sangiardi; Cécile Iborra; Michel Robert Popoff; Michael Seagar; Jacques Fantini; Christian Lévêque; Oussama El Far
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-20       Impact factor: 11.205

4.  Inhibition of botulinum neurotoxin a toxic action in vivo by synthetic synaptosome- and blocking antibody-binding regions.

Authors:  M Zouhair Atassi; Behzod Z Dolimbek; Lance E Steward; K Roger Aoki
Journal:  Protein J       Date:  2010-07       Impact factor: 2.371

Review 5.  Action of botulinum neurotoxins in the central nervous system: antiepileptic effects.

Authors:  Y Bozzi; L Costantin; F Antonucci; M Caleo
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

6.  Synaptotagmin II and gangliosides bind independently with botulinum neurotoxin B but each restrains the other.

Authors:  M Zouhair Atassi; Midori Taruishi; Masooma Naqvi; Lance E Steward; K Roger Aoki
Journal:  Protein J       Date:  2014-06       Impact factor: 2.371

7.  Onset dynamics of type A botulinum neurotoxin-induced paralysis.

Authors:  Frank J Lebeda; Michael Adler; Keith Erickson; Yaroslav Chushak
Journal:  J Pharmacokinet Pharmacodyn       Date:  2008-06-13       Impact factor: 2.745

Review 8.  Receptor and substrate interactions of clostridial neurotoxins.

Authors:  Axel T Brunger; Andreas Rummel
Journal:  Toxicon       Date:  2009-03-04       Impact factor: 3.033

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.